Multiple sclerosis: pharmacogenomics and personalised drug treatment

被引：0
作者：
V. Annibali
G. Ristori
S. Cannoni
S. Romano
A. Visconti
A. Ghazaryan
L. Figà Talamanca
M. Salvetti
R. Mechelli
机构：
[1] Ospedale S. Andrea,Department of Neurology and Centro Neurologico Terapia Sperimentale (CENTERS)
[2] University of Rome “La Sapienza”,undefined
来源：
Neurological Sciences | 2006年 / 27卷
关键词：
Pharmacogenomics; Multiple sclerosis; Therapy; Microarrays;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Multiple sclerosis (MS) is a disorder of the central nervous system with an inflammatory and a neurodegenerative component. We do not yet have a definitive therapy for MS. Attempts to develop new treatments are long and costly and should be paralleled by studies aimed at increasing the therapeutic index of the existing treatments, interferon β and glatiramer acetate. Pharmacogenetics and pharmacogenomics may be of use in this respect though their application may not be straightforward, particularly in MS.
引用
收藏
页码：s347 / s349
相关论文
共 50 条
  • [31] Multiple sclerosis - New treatment modalities
    Totaro, Rocco
    Di Carmine, Caterina
    Marini, Carmine
    Carolei, Antonio
    [J]. INDIAN JOURNAL OF MEDICAL RESEARCH, 2015, 142 : 646 - 653
  • [32] Monoclonal Antibodies in the Treatment of Multiple Sclerosis
    Di Pauli, F.
    Berger, T.
    Reindl, M.
    [J]. CURRENT MEDICINAL CHEMISTRY, 2009, 16 (36) : 4858 - 4868
  • [33] Update on the treatment options for multiple sclerosis
    Niino, Masaaki
    Sasaki, Hidenao
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2010, 6 (01) : 77 - 88
  • [34] The Danish Multiple Sclerosis Treatment Register
    Magyari, Melinda
    Koch-Henriksen, Nils
    Sorensen, Per Soelberg
    [J]. CLINICAL EPIDEMIOLOGY, 2016, 8 : 549 - 552
  • [35] Trials of antivirals in the treatment of multiple sclerosis
    Lycke, J.
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 2017, 136 : 45 - 48
  • [36] TREATMENT OF MULTIPLE-SCLEROSIS WITH MITOXANTRONE
    MAUCH, E
    KORNHUBER, HH
    KRAPF, H
    FETZER, U
    LAUFEN, H
    [J]. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 1992, 242 (2-3) : 96 - 102
  • [37] Use of mitoxantron in the treatment of multiple sclerosis
    Sivertseva, S. A.
    Zhuravlev, M. N.
    Shmurygina, E. A.
    Dekhtiarenko, E. V.
    Boyko, A. N.
    [J]. ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2009, 109 (07) : 100 - 106
  • [38] Monoclonal Antibodies for Multiple Sclerosis Treatment
    Palavra, Filipe
    [J]. ACTA MEDICA PORTUGUESA, 2015, 28 (05): : 640 - 651
  • [39] Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy
    Hamzic, Seida
    Aebi, Stefan
    Joerger, Markus
    Montemurro, Michael
    Ansari, Marc
    Amstutz, Ursula
    Largiader, Carlo
    [J]. SWISS MEDICAL WEEKLY, 2020, 150
  • [40] Metabolic and safety issues for multiple sclerosis pharmacotherapy - opportunities for personalised medicine
    Wiese, Michael D.
    Suppiah, Vijayaprakash
    O'Doherty, Catherine
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2014, 10 (08) : 1145 - 1159
12345